Watch to learn more about VYNDAMAX

VYNDAMAX® (tafamidis) can help those living with ATTR-CM live longer with fewer heart-related hospital visits

At month 30 in a clinical trial of people with either wild-type or hereditary ATTR-CM, VYNDAMAX was proven to significantly reduce death and the number of heart-related hospitalizations in patients with ATTR-CM compared to those who did not take VYNDAMAX (placebo group).

The clinical studies of VYNDAQEL® (tafamidis meglumine) supported the approval of VYNDAMAX, which contains the same active ingredient.

VYNDAMAX helped more people live longer

Survival rate at month 30

In a clinical trial, VYNDAMAX was proven to significantly reduce death and the number of heart-related hospitalizations in patients with ATTR-CM. Patients in the VYNDAMAX group lived longer than those in the placebo group.

71% and 57%, used to compare VYNDAMAX (tafamidis) survival rate at month 30 for people on treatment and those on a placebo. See safety info.

People who took VYNDAMAX had fewer heart-related hospitalizations

VYNDAMAX was proven to lower the risk of heart-related hospitalizations by 32% compared with placebo.

Ambulance in a downward pointing arrow used to communicate the people that took VYNDAMAX (tafamidis) had fewer heart related hospitalizations. See safety info.

Keep in mind

It's important to remember that even if you don't feel VYNDAMAX working, always tell your doctor how you are feeling. Be reassured that VYNDAMAX has been proven to help adults with ATTR-CM live longer with fewer heart-related hospitalizations.

How was health-related quality of life measured in patients taking VYNDAMAX?

The Kansas City Cardiomyopathy Questionnaire

The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a 23-question survey that evaluates health-related quality of life. In the same clinical trial, people on VYNDAMAX scored better on a number of health measures at month 30 compared with those not taking VYNDAMAX (placebo group).∗

Clipboard showing important data for VYNDAMAX (tafamidis)

∗Patients in the VYNDAMAX and placebo groups had worse KCCQ overall summary scores at month 30 than at the start of the study.

How was heart function and exercise capacity measured in patients taking VYNDAMAX?

The 6-Minute Walk Test

The 6-Minute Walk Test (6MWT) is a test to measure heart function and exercise capacity. At the end of the 30-month clinical trial, people who took VYNDAMAX were able to walk 83 yards (76 meters) more on average in the 6MWT than people who did not take VYNDAMAX (placebo group).†

Illustration depicting the 6 minute walk test, at the end of the clinical trial, people who took VYNDAMAX (tafamidis) were able to walk 83 yards more on average than people who took placebo. See safety info.

†Patients in the VYNDAMAX and placebo groups had worse 6-minute walking distance than at the start of the study.